Viva Biotech Holdings (HK:1873) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Viva Biotech Holdings has announced the successful transformation of its subsidiary Viva Shanghai into a joint-stock company, with the parent company retaining approximately 72.9% interest. Alongside this corporate restructuring, Mr. WANG Zheren has stepped down as Co-Chief Financial Officer to concentrate on his role as CFO of Viva Shanghai, while Mr. XIONG Wei will take over as the sole CFO of the Group.
For further insights into HK:1873 stock, check out TipRanks’ Stock Analysis page.